News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Paolo Tarantino: Taxanes vs Eribulin for First-Line Metastatic HER2+ Breast Cancer
Paolo Tarantino and Tess O'Meara
Jan 26, 2025, 08:08

Paolo Tarantino: Taxanes vs Eribulin for First-Line Metastatic HER2+ Breast Cancer

Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, posted on X about recent paper by him and Tess O’Meara, Hematology/Oncology Fellow at Dana-Farber Cancer Institute, published in Journal of Clinical Oncology:

“1st line treatment for HER2+ mBC, unchanged for >10 years, is finally evolving. EMERALD introduced 1st line eribulin. PATINA introduced palbo. DB09 may soon introduce T-DXd.

In this editorial, Tess O’Meara and I review this evolution and provide suggestions for Rx tailoring.”

“Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study”

Authors: Paolo Tarantino and Tess O’Meara

Paolo Tarantino: Taxanes vs Eribulin for First-Line Metastatic HER2+ Breast Cancer

More posts featuring Paolo Tarantino.

cancer DB09 EMERALD eribulin HER2+ breast cancer OncoDaily Oncology Paolo Tarantino PATINA taxanes Tess O'Meara
Special Coverage
Science
Jan 26, 2025, 08:08
Paolo Tarantino: Taxanes vs Eribulin for First-Line Metastatic HER2+ Breast Cancer
Blog
Jan 26, 2025, 08:06
Dean Crowe: More than $2.5M to amazing pediatric cancer research at Emory University
Blog
Jan 26, 2025, 08:04
Antonio D'Alessio: RACB Study conversion therapy with AtezoBev in initially unresectable HCC
Blog
Jan 26, 2025, 08:02
Sanam Loghavi: An opening for our 2025-2026 Hematopathology Fellowship at MD Anderson Cancer Center
Blog
Jan 26, 2025, 07:45
Fadi Haddad: The first edition of the Pan Pacific Leukemia conference in Maui
Blog
Jan 26, 2025, 07:43
Pat Price: We cannot accept a two-tiered system where if you can’t pay you face delays
Blog
Jan 26, 2025, 07:40
2 million dollars from 24 Foundation to support cancer survivorship at Atrium Health Levine Cancer Institute
Blog
Jan 26, 2025, 07:36
Gevorg Tamamyan: BGICC is a GREAT success
Blog
Jan 26, 2025, 07:35
Amol Akhade: Additon of trastuzumab With or without Pertuzumab in her2 postive stomach cancer
Blog
Jan 26, 2025, 07:32
Elvina Almuradova: Waist circumference and waist-to-hip ratio as predictors of colorectal cancer risk
Blog
Jan 26, 2025, 07:30
Stijn Vanstraelen: First robotic esophagectomy for cancer performed at UZ Leuven
Blog
Jan 26, 2025, 07:27
Karen Knudsen: Clinical trials driving cancer care breakthroughs